INTRODUCTION: Paediatric non-commercial interventional clinical trials (NICTs) are crucial for healthcare provision. In spite of the fact that current regulations and initiatives try to enhance the quantity and quality of paediatric NICTs, there are still shortcomings that need to be addressed in order to accelerate the conduct of relevant clinical trials in children. To improve the current landscape of paediatric clinical research, it is necessary to identify and analyse the main trends and shortcomings, along with their impact on national performance in paediatric NICTs and this is the aim of this work. METHOD: A retrospective systematic search of paediatric NICTs was performed on four international clinical trials registries. Entries were filtered by date from 01/01/2004 to 31/12/2017. Each identified paediatric NICT was screened and analysed for sponsors, funders, type of intervention, therapeutic area, design characteristics and associated publications. RESULTS: The search identified 439 unique NICTs. When stratifying the trials by enrolment ages, 86 trials were found involving the paediatric population. Most trials investigated the use of medicinal products and were focused on cancer or cardiovascular diseases. The most common sources of the funding were non-profit organizations. Furthermore, from the total number of completed trials, only half of them already published their results. CONCLUSION: The main shortcomings-specifically, ethical, methodological and, in particular, economic obstacles were identified. There is a continual need for greater support and collaboration between all major stakeholders including health policymakers, grant agencies, research institutions, pharmaceutical industries and healthcare providers at the national and international level.

Department of Applied Pharmacy Faculty of Pharmacy University of Veterinary and Pharmaceutical Sciences Brno Brno Czech Republic

Department of Clinical Trials Masaryk Memorial Cancer Institute Brno Brno Czech Republic

Department of Pharmacology Faculty of Medicine Masaryk University Kamenice 753 5 625 00 Brno Czech Republic

Department of Physiology Faculty of Medicine Masaryk University Brno Czech Republic

European Clinical Research Infrastructure Network Paris France

University Hospital St Anne's Brno International Clinical Research Center Brno Czech Republic

See more in PubMed

Convention on the Rights of the Child. UN General Assembly. 1989. https://www.refworld.org/docid/3ae6b38f0.html. Accessed 9 May 2020

Hawcutt DB, Cooney L, Oni L, Pirmohamed M. Precision dosing in children. Expert Rev Precis Med Drug Dev. 2016;1:69–78. doi: 10.1080/23808993.2016.1138845. DOI

Corny J, Bailey B, Lebel D, Bussières J-F. Unlicensed and off-label drug use in paediatrics in a mother-child tertiary care hospital. Paediatr Child Health. 2016;21:83–87. doi: 10.1093/pch/21.2.83. PubMed DOI PMC

Ferro A. Paediatric prescribing: why children are not small adults. Br J Clin Pharmacol. 2015;79:351–353. doi: 10.1111/bcp.12540. PubMed DOI PMC

Stephenson T. How children’s responses to drugs differ from adults. Br J Clin Pharmacol. 2005;59:670–673. doi: 10.1111/j.1365-2125.2005.02445.x. PubMed DOI PMC

Mulugeta Y, Zajicek A, Barrett J, Sachs HC, McCune S, Sinha V, Yao L. Development of drug therapies for newborns and children. Pediatr Clin N Am. 2017;64:1185–1196. doi: 10.1016/j.pcl.2017.08.015. PubMed DOI PMC

Wimmer S, Neubert A, Rascher W. The safety of drug therapy in children. Dtsch Aerzteblatt Online. 2015 doi: 10.3238/arztebl.2015.0781. PubMed DOI PMC

Evens RP, editor. Drug and Biological Development. Boston: Springer; 2007.

Park MS. Regulatory innovation for expansion of indications and pediatric drug development. Transl Clin Pharmacol. 2018;26:155. doi: 10.12793/tcp.2018.26.4.155. PubMed DOI PMC

Tamimi NAM, Ellis P. Drug development: from concept to marketing! Nephron Clin Pract. 2009;113:c125–c131. doi: 10.1159/000232592. PubMed DOI

Bavdekar S. Pediatric clinical trials. Perspect Clin Res. 2013;4:89. doi: 10.4103/2229-3485.106403. PubMed DOI PMC

Li JS, Eisenstein EL, Grabowski HG, Reid ED, Mangum B, Schulman KA, Goldsmith JV, Murphy MD, Califf RM, Benjamin DK. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA. 2007;297:480. doi: 10.1001/jama.297.5.480. PubMed DOI PMC

Cavalla D. Off-Label Prescribing: Justifying Unapproved Medicine. Chichester: Wiley; 2015.

Collier J. Paediatric prescribing: using unlicensed drugs and medicines outside their licensed indications. Br J Clin Pharmacol. 1999;48:5–8. doi: 10.1046/j.1365-2125.1999.00983.x. PubMed DOI PMC

Lavan M, Byrn SR, Knipp G. Pediatric formulations: knowledge gaps limiting the expedited preclinical to clinical translation in children. AAPS PharmSciTech. 2019;20:73. doi: 10.1208/s12249-018-1253-3. PubMed DOI

Khan-Boluki J, Hundt F. Children in clinical trials: survey on the current situation in paediatric university clinics in Germany. Ger Med Sci GMS E-J. 2008;6:Doc01. PubMed PMC

European Union. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. 26 January 2007.

Regulation (EC) No 1902/2006 of the European Parliament and of the Council of 12 December 2006 amending Regulation 1901/2006 on medicinal products for paediatric use.

Penkov D, Tomasi P, Eichler I, Murphy D, Yao LP, Temeck J. Pediatric medicine development: an overview and comparison of regulatory processes in the European Union and United States. Ther Innov Regul Sci. 2017;51:360–371. doi: 10.1177/2168479017696265. PubMed DOI PMC

Permanand G, Mossialos E, McKee M. The EU’s new paediatric medicines legislation: serving children’s needs? Arch Dis Child. 2007;92:808–811. doi: 10.1136/adc.2006.105692. PubMed DOI PMC

De Angelis C, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med. 2004;351:1250–1251. doi: 10.1056/NEJMe048225. PubMed DOI

Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug–drug comparisons: why some statins appear more efficacious than others. PLoS Med. 2007;4:e184. doi: 10.1371/journal.pmed.0040184. PubMed DOI PMC

Madeira C, Santos F, Kubiak C, Demotes J, Monteiro EC. Transparency and accuracy in funding investigator-initiated clinical trials: a systematic search in clinical trials databases. BMJ Open. 2019;9:e023394. doi: 10.1136/bmjopen-2018-023394. PubMed DOI PMC

Hartmann M, Hartmann-Vareilles F. The clinical trials directive: how is it affecting Europe’s Noncommercial Research. PLoS Clin Trials. 2006;1:e13. doi: 10.1371/journal.pctr.0010013. PubMed DOI PMC

Minisman G, Bhanushali M, Conwit R, Wolfe GI, Aban I, Kaminski HJ, Cutter G. Implementing clinical trials on an international platform: challenges and perspectives. J Neurol Sci. 2012;313:1–6. doi: 10.1016/j.jns.2011.10.004. PubMed DOI PMC

Konwar M, Bose D, Gogtay NJ, Thatte UM. Investigator-initiated studies: challenges and solutions. Perspect Clin Res. 2018;9:179–183. PubMed PMC

Ravinetto R, De Nys K, Boelaert M, Diro E, Meintjes G, Adoke Y, Tagbor H, Casteels M. Sponsorship in non-commercial clinical trials: definitions, challenges and the role of Good Clinical Practices guidelines. BMC Int Health Hum Rights. 2015 doi: 10.1186/s12914-015-0073-8. PubMed DOI PMC

Janiaud P, Cristea I-A, Ioannidis JPA. Industry-funded versus non-profit-funded critical care research: a meta-epidemiological overview. Intensive Care Med. 2018;44:1613–1627. doi: 10.1007/s00134-018-5325-3. PubMed DOI PMC

European Commission, Clinical trials - Regulation EU No 536/2014. https://ec.europa.eu/health/human-use/clinical-trials/regulation_en.

State of Paediatric Medicines in the EU 10 years of the EU Paediatric Regulation. Commission to the European Parliament and the Council. 2017. https://ec.europa.eu/health/sites/health/files/files/paediatrics/docs/2017_childrensmedicines_report_en.pdf. Accessed 24 Jan 2020

European Parliament resolution of 15 December 2016 on the regulation on paediatric medicines. https://www.europarl.europa.eu/doceo/document/TA-8-2016-0511_EN.html.

Better Medicines for Children From Concept to Reality, General Report on experience acquired as a result of the application of Regulation (EC) n° 1901/2006 on medicinal products for paediatric use. 2013. https://ec.europa.eu/health/sites/health/files/files/paediatrics/2013_com443/paediatric_report-com%282013%29443_en.pdf. Accessed 9 May 2020.

-year Report to the European Commission. European Medicines Agency and its Paediatric Committee. 2016. https://ec.europa.eu/health/sites/health/files/files/paediatrics/2016_pc_report_2017/ema_10_year_report_for_consultation.pdf. Accessed 9 May 2020

Study on the economic impact of the Paediatric Regulation, including its rewards and incentives. Technopolis group Ecorys Nederland BV empirica GmbH. 2016. https://ec.europa.eu/health/sites/health/files/files/paediatrics/docs/paediatrics_10_years_economic_study.pdf. Accessed 5 May 2020

Clinical Trials Directive 2001/20/EC, European Commission.

Welzing L, Harnischmacher U, Weyersberg A, Roth B. Consequences of Directive 2001/20/EC for investigator-initiated trials in the paediatric population—a field report. Eur J Pediatr. 2007;166:1169–1176. doi: 10.1007/s00431-007-0434-y. PubMed DOI

Czech health research council. https://www.azvcr.cz/en.

Lee K-H. The conceptualization of country attractiveness: a review of research. Int Rev Adm Sci. 2016;82:807–826. doi: 10.1177/0020852314566002. DOI

The European & Developing Countries Clinical Trials Partnership. https://www.edctp.org/funding-opportunities/. PubMed PMC

Innovation Fund Denmark. https://innovationsfonden.dk/en.

Lepola P, Needham A, Mendum J, Sallabank P, Neubauer D, de Wildt S. Informed consent for paediatric clinical trials in Europe. Arch Dis Child. 2016;101:1017–1025. doi: 10.1136/archdischild-2015-310001. PubMed DOI PMC

Madeira C, Pais A, Kubiak C, Demotes J, Monteiro EC. Investigator-initiated clinical trials conducted by the Portuguese Clinical Research Infrastructure Network (PtCRIN) Contemp Clin Trials Commun. 2016;4:141–148. doi: 10.1016/j.conctc.2016.08.002. PubMed DOI PMC

World Medical Association Declaration of Helsinki Ethical principles for medical research involving human subjects. JAMA. 2013;310:2191. doi: 10.1001/jama.2013.281053. PubMed DOI

DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet. 2020;395:361–369. doi: 10.1016/S0140-6736(19)33220-9. PubMed DOI

Investigator-driven clinical trials forward look. European Science Foundation, Strasbourg. Fondation européenne de la science. 2009. https://archives.esf.org/fileadmin/Public_documents/Publications/IDCT.pdf. Accessed 5 May 2020.

Alemayehu C, Mitchell G, Nikles J. Barriers for conducting clinical trials in developing countries—a systematic review. Int J Equity Health. 2018;17:37. doi: 10.1186/s12939-018-0748-6. PubMed DOI PMC

Intini A, Bonifazi D, Migliaccio G. Challenges and new frontiers in the paediatric drug discovery and development. Drug Discov Dev. 2020 doi: 10.5772/intechopen.85635. DOI

Nevens H, Harrison J, Vrijens F, Verleye L, Stocquart N, Marynen E, Hulstaert F. Budgeting of non-commercial clinical trials: development of a budget tool by a public funding agency. Trials. 2019;20:714. doi: 10.1186/s13063-019-3900-8. PubMed DOI PMC

The European Clinical Research Infrastructure Network. https://www.ecrin.org/.

Paediatric Clinical Research Infrastructure Network. https://www.ecrin.org/projects/pedcrin.

Czech Clinical Research Infrastructure Network. https://www.czecrin.cz/czecrin-en.

TA ČR Starfos. https://starfos.tacr.cz/en/project/LM2013034.

Large research infrastructures supported by the Ministry of Education, Youth and Sports of the Czech Republic. https://www.vyzkumne-infrastruktury.cz/en/biomedical-sciences/czecrin/.